SAB Biotherapeutics, Inc.

NasdaqCM:SABS Stock Report

Market Cap: US$16.8m

SAB Biotherapeutics Future Growth

Future criteria checks 2/6

SAB Biotherapeutics's earnings are forecast to decline at 13.7% per annum while its annual revenue is expected to grow at 61.5% per year. EPS is expected to grow by 31.8% per annum.

Key information

-13.7%

Earnings growth rate

31.8%

EPS growth rate

Biotechs earnings growth28.8%
Revenue growth rate61.5%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Jan 2025

Recent future growth updates

Recent updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

Earnings and Revenue Growth Forecasts

NasdaqCM:SABS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271-68-68-614
12/31/20261-55-57-464
12/31/20251-47-48-395
12/31/20241-34-43-355
9/30/20242-46-39-38N/A
6/30/20243-40-37-37N/A
3/31/20243-40-35-34N/A
12/31/20232-42-25-25N/A
9/30/20234-27-13-13N/A
6/30/20236-29-16-16N/A
3/31/202313-27-16-16N/A
12/31/202224-19-26-23N/A
9/30/202233-22-31-27N/A
6/30/202244-19-23-15N/A
3/31/202256-18-27-17N/A
12/31/202161-17-92N/A
9/30/2021767-311N/A
6/30/20217817-413N/A
3/31/20216621619N/A
12/31/20205520-310N/A
12/31/20193-9-10-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SABS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SABS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SABS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SABS's revenue (61.5% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: SABS's revenue (61.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SABS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 22:50
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SAB Biotherapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC